From thalidomide to resveratrol, molecules with the exact same chemical properties can have drastically different effects in the body depending on how they’re arranged in space.
Academic rigour, journalistic flair
Articles on Thalidomide
Displaying 1 - 20 of 29 articles
Many approved drugs work on the body in ways that researchers still aren’t entirely clear about. Seeing this as an opportunity instead of a flaw may lead to better treatments for complex conditions.
Drug repurposing can redeem failed treatments and squeeze out new uses from others. But many pharmaceutical companies are hesitant to retool existing drugs without a high return on investment.
The FDA receives almost half its funding from companies it regulates, such as drug and medical device makers. Is this something you should be concerned about?
Evans is admired for his fearless leadership and tireless campaigning journalism.
The infamous drug can inhibit the body’s inflammatory response, which is why researchers wonder if it can effectively treat COVID-19.
As the measles outbreaks spread, public health officials are trying different measures to curb it. Yet there are limits to what they can do as they balance community safety and personal freedom.
A new book, ‘The Thalidomide Catastrophe,’ raises new questions about the conduct of corporations involved. It is the duty of governments to find out the answers.
Virtually every medical therapy in use today owes its existence to animal experiments. But we can’t assume what works in animals will in humans. And sometimes, the mismatch can be dangerous.
We still don’t know what’s behind four out of every five birth defects. But that can change.
The randomised controlled trial is touted as the gold standard in medical research. But its controlled laboratory conditions are far removed from the messy realities of life.
The MHRA has opened an inquiry on the once popular pregnancy test pills. Did they really cause birth defects in children born in the 1970s?
This was the year of the health review – mental health care, Medicare, private health insurance, the pharmacy industry … and the list goes on. But how much movement was there on policy?
Thalidomide is notorious for causing death and disability but it – and its derivatives – are proving useful for conditions such as leprosy.
The thalidomide tragedy changed how medicines are viewed during pregnancy – not only by pregnant women, but also the wider community.
Tighter regulations of medicines and devices have prevented countless deaths and disabilities. But regulation can’t always protect us from harm.
Thalidomide was responsible for one of the biggest drug disasters in history. It is making a comeback. But is Africa equipped to handle this controversial drug?
Reactions to the thalidomiders’ difference contributed – and continue to contribute – to their negative well-being and deteriorating health.
Decades have passed and yet the issue of financial compensation for the remaining “survivors” of the thalidomide tragedy has, in many instances, remained unresolved.
Journalist-turned-lawyer Michael Magazanik worked on recent Australian thalidomide lawsuits. As part of our series on the drug, he spoke to Ian Freckelton about the book he wrote, based on the case.
Job Board
-
Lecturer / Senior Lecturer, Emerging Technologies
-
Teaching Fellow / Senior Teaching Fellow
-
DOHERTY INSTITUTE DEPUTY DIRECTOR (RESEARCH AND ENGAGEMENT)
-
Academic Heads (x3)
-
Business Journalist
Top contributors
-
Assistant Director of Pharmacy, Mater Health SEQ in conjoint appointment as Associate Professor of Pharmacology, Bond University and Associate Professor (Clinical), The University of Queensland
-
Professor in Developmental Biology, University of Aberdeen
-
Associate Professor of History, University of Wollongong
-
Senior Research Fellow, Bioethics, University of Sydney
-
Adjunct Professor, Australian Centre for Health Law Research, School of Law, Queensland University of Technology
-
Lecturer in History of Medicine/Life Science, The University of Melbourne
-
Associate Professor, Cumming School of Medicine, University of Calgary
-
Head, Cancer Research Program, Monash University
-
Emeritus Professor of Journalism, Cardiff University
-
Health Services Researcher, The University of Melbourne
-
Professorial Fellow in Law, The University of Melbourne
-
Honorary Professor in History, University of KwaZulu-Natal
-
Director, Lemelson Center for the Study of Invention and Innovation, Smithsonian Institution
-
Assistant Professor, Sociology, University of Victoria
-
Manager, Cancer Research Program, Monash University
